Oramed’s Corporate Defense: A Biotech’s Battle for Autonomy

A biotech firm suddenly flush with cash and developing a revolutionary medical treatment typically represents an investor’s ideal scenario. However, the current narrative at Oramed Pharmaceuticals is dominated not by scientific progress, but by a significant corporate power struggle. As the company announces record-breaking profits, its leadership is taking decisive action to shield itself from potential acquisition.

The Real Story Behind the Financial Surge

Oramed’s latest financial report has captured industry attention with a dramatic reversal of fortune. For the initial three quarters of 2025, the company posted a substantial profit of $65 million, a stark contrast to the $6.1 million loss previously recorded. This impressive turnaround, however, stems not from product sales but from strategic financial activities. The bolstered balance sheet reflects realized gains from its Scilex holding and unrealized appreciation in equity investments, including its stake in Alpha Tau Medical.

This newfound financial strength presents a double-edged sword. The strengthened financial position and substantial cash reserves have ironically made Oramed an attractive target for potential acquirers.

Implementing a Takeover Defense Strategy

In a strategic countermove, Oramed’s board of directors enacted a Rights Agreement this Monday—a well-known corporate defense mechanism against hostile takeovers. This plan grants shareholders a purchase right for each share they own, which becomes exercisable under specific conditions. The mechanism’s core feature activates when any single investor accumulates more than 15% of the company’s shares, triggering other shareholders’ ability to purchase additional shares at a discounted price of $10. This provision would dramatically increase the acquisition cost for any potential buyer.

Should investors sell immediately? Or is it worth buying Oramed?

The implementation of this protective measure underscores management’s serious concern about external threats. The timing is particularly telling, coming shortly after the company published its robust financial results.

The Core Value Proposition: Oral Insulin Development

Amidst market speculation about potential corporate battles, Oramed continues to advance its primary technological innovation: ORMD-0801, an orally administered insulin formulation. Following the dissolution of a joint venture with a Chinese partner, the company has assumed full control over the development program and is initiating a new clinical trial.

The central question remains whether Oramed will successfully shepherd its groundbreaking oral delivery technology to commercialization independently. Alternatively, could its promising drug portfolio eventually be absorbed by a larger pharmaceutical entity? The coming weeks will reveal the effectiveness of these defensive measures—and whether the company’s financial appeal ultimately outweighs any protective mechanism.